

PRESS RELEASE

STOCKHOLM, 22 APRIL 2026 11:10 CEST

Invitation to presentation of RaySearch's interim report for the first quarter of 2026

RaySearch will publish its report for the first quarter of 2026 on Wednesday, April 29, at 7:30 a.m. CEST. A webcast presentation will be held at 11:00 a.m. on the same day.

Johan Löf, founder and CEO, and Nina Grönberg, CFO, will present and comment on the report. The presentation will be held in English, followed by a Q&A session. Questions may also be submitted in writing to ir@raysearchlabs.com.

Follow the webcast presentation live at: [Q1 presentation 2026](#)

Please make sure you are connected to the presentation by logging in a few minutes before it starts. The presentation materials, along with the report and a recording of the presentation, will be made available on RaySearch's website.

Welcome!

For more information, please contact:

Carolina Strömlid, Head of Investor Relations

Tel: +46 (0) 708 807 173

ir@raysearchlabs.com

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to nearly 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets.

Learn more about us on:

[LinkedIn](#)

[YouTube](#)